Volitionrx Ltd (VNRX) - Total Liabilities
Based on the latest financial reports, Volitionrx Ltd (VNRX) has total liabilities worth $42.49 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Volitionrx Ltd (VNRX) cash conversion ratio to assess how effectively this company generates cash.
Volitionrx Ltd - Total Liabilities Trend (2004–2025)
This chart illustrates how Volitionrx Ltd's total liabilities have evolved over time, based on quarterly financial data. See Volitionrx Ltd shareholders equity for net asset value and shareholders' equity analysis.
Volitionrx Ltd Competitors by Total Liabilities
The table below lists competitors of Volitionrx Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Epsium Enterprise Limited Ordinary Shares
NASDAQ:EPSM
|
USA | $1.59 Million |
|
TEAM PLC
F:1WQ
|
Germany | €5.29 Million |
|
LiqTech International Inc
NASDAQ:LIQT
|
USA | $16.91 Million |
|
LL Lucky Games publ AB
ST:LADYLU
|
Sweden | Skr35.38 Million |
|
Nexen Tire Prf 1
KO:002355
|
Korea | ₩2.95 Trillion |
|
Lammhults Design Group AB (publ)
ST:LAMM-B
|
Sweden | Skr314.40 Million |
|
Dev Information Technology Limited
NSE:DEVIT
|
India | Rs782.38 Million |
|
Eureka Design Public Company Limited
BK:UREKA
|
Thailand | ฿324.34 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Volitionrx Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Volitionrx Ltd stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 6.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Volitionrx Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Volitionrx Ltd (2004–2025)
The table below shows the annual total liabilities of Volitionrx Ltd from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $42.49 Million | +19.68% |
| 2024-12-31 | $35.51 Million | -3.15% |
| 2023-12-31 | $36.66 Million | +71.15% |
| 2022-12-31 | $21.42 Million | +119.30% |
| 2021-12-31 | $9.77 Million | -0.90% |
| 2020-12-31 | $9.86 Million | +38.97% |
| 2019-12-31 | $7.09 Million | +32.61% |
| 2018-12-31 | $5.35 Million | +14.61% |
| 2017-12-31 | $4.67 Million | +31.17% |
| 2016-12-31 | $3.56 Million | +113.35% |
| 2015-12-31 | $1.67 Million | -45.59% |
| 2014-12-31 | $3.06 Million | +120.48% |
| 2013-12-31 | $1.39 Million | +0.51% |
| 2012-12-31 | $1.38 Million | +19.60% |
| 2011-12-31 | $1.16 Million | +907.47% |
| 2010-12-31 | $114.77K | +3.42% |
| 2009-12-31 | $110.98K | +11.83% |
| 2008-12-31 | $99.24K | +20.06% |
| 2007-12-31 | $82.66K | +41.34% |
| 2006-12-31 | $58.48K | -19.93% |
| 2005-12-31 | $73.04K | +13.95% |
| 2004-12-31 | $64.10K | -- |
About Volitionrx Ltd
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleos… Read more